Oncodesign SA, a
Oncodesign S.A, a French privately-held biotechnology company and one of the leading providers of preclinical services in Oncology, announced today a $4.7 million (Euros 3 million) financing led by new investor “Vizille Capital Innovation“. An existing investor “Avenir Entreprises“ was also participating to this financing round.
Oncodesign will use the proceeds from this financing to complete their growth in North-America as well as to enhance their leading position as a partner of choice for biotechnology and pharmaceutical companies to develop new anticancer drugs from discovery and preclinical stage to first clinical trials in man.
“We are delighted to have Vizille Capital Innovation as an investor. Not only does Vizille Capital Innovation has outstanding experience in the biotechnology market, they are well-poised to significantly step up our international growth” said Philippe Genne, Ph.D., Chairman and Chief Executive Officer of Oncodesign. “This financing is a clear recognition of the value of Oncodesign's unparalleled experience and expertise as well as our potential of growth”.
“Vizille Capital Innovation's focus is on companies with strong domain expertise. We are very impressed with the Oncodesign's unique technology platform that was designed from its inception to discover, to validate and to speed-up the development of new drugs in Oncology” said Karine Lignel, Investment Director of Vizille Capital Innovation. “We are enthusiastic to contribute our financial and strategic resources to this promising company”.
About Vizille Capital Innovation
CIC – Vizille Capital Innovation is the venture capital subsidiary of the CIC – Banque de Vizille Group. Its objective is to invest in promising technology companies in their early stages of development with a high growth potential in dynamic sectors such as information technologies, telecommunications, electronics, life sciences, new materials, and the environment. CIC